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The Epstein-Barr virus (EBV) immediate-early gene product, BRLF1, transactivates the human immuno-
deficiency virus type 1 (HIV-1) long terminal repeat. BRLFl-induced transactivation of HIV-1 promoter
constructs is accompanied by an increase in plasmid mRNA and is reporter gene independent. Previously,
BRLF1 transactivation of EBV promoters has been mapped to regions which function as enhancer elements.
Deletional analysis demonstrates that BRLF1 transactivation of the HIV-1 promoter does not require the HIV-1
enhancer. Thus, the EBV BRLF1 gene product may transactivate by at least two different mechanisms, one
mechanism involving certain enhancer elements and another mechanism which is enhancer independent.
Epstein-Barr virus (EBV) is a 170-kilobase herpesvirus
which can produce either latent or lytic infection in human B
cells (3, 23), epithelial cells (31), and T cells (19, 30).
Although each of the three EBV immediate-early (IE) genes
(BZLF1, BRLF1, and BMLF1) has now been shown to
possess transactivating functions (4-7, 13, 15, 17, 18, 20, 33,
36, 37), the effect of each IE transactivator on homologous
and heterologous promoters is distinct. The BZLF1 IE gene
product, which has homology to the c-fos gene product and
can bind to the consensus AP-1 site (9), has been shown to
transactivate several EBV early promoters and downregu-
late the BamHI C and BamHI W EBV nuclear antigen
promoters (5, 14). The BZLF1 gene product alone (when
placed under the control of a strong heterologous promoter)
is sufficient to disrupt viral latency in EBV-infected lym-
phoid cells (33). The BMLF1 IE gene product has been
demonstrated to increase the chloramphenicol acetyltrans-
ferase (CAT) activity driven by a variety of homologous and
heterologous promoters (18, 20, 37), including the human
immunodeficiency virus type 1 (HIV-1) long terminal repeat
(LTR). However, the BMLF1 effect has been recently
shown to be mediated by a posttranscriptional mechanism
which is reporter gene dependent (16, 21a) and whose
function in EBV infection remains unknown.
The most recently described EBV IE transactivator,
BRLF1, has been shown to transactivate three EBV promot-
ers (the BMLF1 IE promoter, the BHRF1 early promoter,
and the DR early promoter) (6, 13, 14) and is likely to
mediate, at least in part, the switch from latent to productive
EBV infection (4, 5, 14, 21, 35). Interestingly, the BMLF1,
BHRF1, and DR promoters have each been recently shown
to have upstream enhancer elements, and the BRLF1 re-
sponse region in each promoter has been mapped to these
enhancer elements. A 14-base-pair sequence (with a 1-base-
pair mismatch) has been found in each of these three
BRLF1-responsive enhancers (14). Consequently, the
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BRLF1 gene product has been referred to as an enhancer
factor (21, 35).
In this paper we report that a fourth promoter, the LTR of
HIV-1, is also responsive to the EBV BRLF1 transactivator.
We show that BRLF1-induced transactivation of HIV-1
promoter constructs is accompanied by a similar increase in
plasmid mRNA and is reporter gene independent, unlike the
previously reported effect of the BMLF-1 transactivator (16,
17, 21a). We demonstrate by deletional analysis that BRLF1
transactivation of the HIV-1 promoter does not require the
presence of the HIV-1 enhancer. Thus, the EBV IE BRLF1
gene product may transactivate by at least two different
mechanisms, one mechanism involving the activation of
certain enhancer elements and another mechanism which is
enhancer independent.
Transactivation of the HIV-1 LTR by the BRLF1 gene
product was demonstrated in transient cotransfection assays
using several different cell types. An HIV-1 LTR CAT
construct (pU3R-III; a gift of C. Rosen and W. Haseltine)
(32) was cotransfected with either the pGEM2 vector con-
taining the cytomegalovirus IE promoter alone (pHD1013;
gift of M. Davis and E.-S. Huang) (8) or a pUC18 vector
containing the BRLF1 transactivator driven by the cytomeg-
alovirus IE promoter (pEBV-RIE) (14). Transfection into all
cell types was performed by the electroporation method (34)
at 1,500 V with a Zapper electroporation unit from the
Medical Electronics Shop, University of Wisconsin, Madi-
son. In each experiment, 107 cells were transfected with 5 ,ug
of each plasmid. After 48 h, the cells were harvested and
extracts of the cells were incubated at 37°C in the presence
of 14C-labeled chloramphenicol and acetyl coenzyme A as
previously described (12). The amount of extract used for
each CAT assay was adjusted to keep the total CAT activity
after cotransfection of the CAT plasmids with pEBV-RIE
within the linear range. After thin-layer chromotography, the
percent acetylation of chloramphenicol was quantitated by
autoradiography and scintillation counting.
The initial preliminary set of experiments revealed that the
activity of the pU3R-III-CAT construct was increased in the
presence of the EBV BRLF1 IE gene product in several
different cell types, including the Jurkat T-cell line, the
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TABLE 1. Effect of pEBV-RIE on pU3R-III 5' deletion and
site-directed mutant plasmids in Jurkat cell lines
Fold increase in CAT activitya
Plasmid type
Avg Range
5' Deletion (n = 3)






Mutant (n = 2)
pU3R-III (n = 3) 14.5 5.1-29.8
pAKB 15.1 13.4-16.7
pATATA 5.7 3.8-7.5
" Calculated by comparing the percent acetylation obtained after cotrans-
fection with the pEBV-RIE (BRLF1) plasmid with that obtained after using
the pHD1013 vector. The average fold increases in the intact HIV-1 LTRs,
determined in three different cell lines, were as follows: Jurkat (n = 3), 14.5
(range, 5.1 to 29.8); Louckes (n = 2), 12.4 (range, 7.5 to 15.7); HeLa (n = 1),
6.5.
EBV-negative Louckes B-cell line, and the HeLa epithelial-
cell line (Table 1). Since the effect of the BRLF1 transacti-
vator on HIV-1 promoter activity was greatest in Jurkat
cells, Jurkat cells were used for the remainder of the
experiments. In each cell type tested, the stimulatory effect
of the BRLF1 transactivator on the HIV-1 promoter was less
than its effect on the homologous EBV BMLF1 IE promoter
(14). However, BRLF1-induced transactivation of the HIV-1
promoter was consistently observed, whereas a variety of
other promoters (including the Rous sarcoma virus and the
EBV BamHI W and BamHI C nuclear antigen promoters)
were not found to be transactivated by BRLF1 (data not
shown).
The ability of the BRLF1 gene product to transactivate the
HIV-1 LTR at the mRNA level was confirmed using the
primer extension method (Fig. 1). The pU3R-III plasmid (5
,ug) was cotransfected into Jurkat cells with 5 ,ug of either
pHD1013 or pEBV-RIE. Cytoplasmic RNA was harvested
24 h after transfection (10) and hybridized to a -y-32P-labeled
primer homologous to the CAT gene sequences 15 to 34 base
pairs downstream of the ATG codon, and primer extension
was performed (22). The expected primer extension product
was 165 base pairs. In the presence of the BRLF1 transac-
tivator (Fig. 1, lane C), the pU3R-III-CAT mRNA was
shown to be initiated at the expected start site, and the
quantity ofCAT mRNA was increased. In contrast, the EBV
BMLF1 transactivator was shown to increase HIV-1-di-
rected CAT activity but did not significantly increase the
level of CAT mRNA (17).
In an attempt to detect specific sites in the HIV-1 pro-
moter required for BRLF1 responsiveness, the pEBV-RIE
plasmid was next cotransfected into Jurkat cells with a series
of HIV-1 LTR 5' deletion mutants linked to the reporter gene
CAT (a gift from Craig Rosen and W. Haseltine) (29). The
deletion plasmids tested, which were named to reflect the
number of base pairs present relative to the mRNA start site,
were as follows: p-167/-17 (5' deletion of 286 nucleotides
and deletion of the 3' tat-responsive region); p-120/+80 (5'
deletion of 333 nucleotides); p-104/+80 (5' deletion of 349
nucleotides); p-57/+80 (5' deletion of 396 nucleotides,
which removed the two KB enhancer sites and two of the
three Spl sites); and p-44/+80 (5' deletion of 408 nucleo-
tides, which removed the last Spl site). Each deletion
FIG. 1. Primer extension detection of pHIV-CAT mRNA levels.
The pHIV-CAT plasmid (5 p.g) was cotransfected into 107 Jurkat
cells with 5 ,ug of either pHD1013 (lane B) or pEBV-RIE (lane C).
Lane A contains mock-transfected cells. Cytoplasmic RNA was
harvested as previously described (2). Lysis of the cells by Nonidet
P-40 was followed by digestion with proteinase K in the presence of
sodium dodecyl sulfate, extraction with phenol-chloroform, and
DNAase treatment. A 20-base oligonucleotide sequence comple-
mentary to the CAT gene in the region 15 to 34 bases downstream of
the ATG codon was synthesized and labeled with [-y-32P]ATP.
Labeled oligonucleotide (105 cpm) was hybridized overnight with 50
p.g of RNA at 30°C in a solution containing 80% formamide, 40 mM
PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid)] (pH 6.4), 400
mM NaCl, and 1 mM EDTA. Primer extension was then performed
at 42°C for 90 min with avian myeloblastosis reverse transcriptase as
previously described (22). After RNase digestion, the primer exten-
sion products were electrophoresed on a 6% acrylamide-urea gel.
Numbers on the right indicate size in base pairs. The expected size
of the primer extension product is shown (arrow).
mutant was cotransfected with pHD1013 or pEBV-RIE, and
the CAT activity was determined. We did not demonstrate
that a single specific region of the HIV-1 promoter is
essential for BRLF1 responsiveness (Table 1). Each of the
series of 5' deletions, including the plasmids which did not
contain the KB enhancer sequence (p-57/+80 and p-44/
+80), was activated 3.2- to 8.5-fold by the BRLF1-con-
taining plasmid, pEBV-RIE.
Two additional plasmids containing mutant sequences of
the HIV-1 LTR produced by site-directed mutagenesis (gifts
from G. Nabel) within the two KB sites (pAKB) (25) or the
TATA sequence (pATATA) (26) were also tested for the
ability to respond to the BRLF1 transactivator (Table 1).
The TATA mutation, which contains GCGC in place of the
TATA sequence, was transactivated 5.7-fold (mean of two
experiments) by BRLF1. The KB mutation, which affects
both KB sites and abolishes the phorbol myristate acetate
responsiveness of the promoter, was transactivated 15-fold.
Thus, neither the KB enhancer element nor the TATA box
element is essential for BRLF1-induced transactivation of
the HIV-1 promoter.
We also used a P-galactosidase (GAL)-HIV-1 LTR con-
struct (gift of D. Markovitz) to evaluate reporter gene
dependence of the BRLF1 transactivator. The HIV-1 LTR-







TABLE 2. Effect of BRLF1 transactivator (pEBV-RIE) on intact
HIV-1 LTR as determined by CAT and GAL assays
CAT activity (% acetylation) GAL activity (AA/min) with
Expt with transactivator plasmid transactivator plasmid
no.
pHD1O13 pEBV-RIE pEBV-RIEno.pHD1013 (fold increase) pHD1013 (fold increase)
1 5.6 74.6 (13.3) 0.0004 0.0041 (10.2)
2 5.5 50.5 (9.2) 0.0005 0.0057 (11.6)
3 1.2 17.6 (14.7) 0.0004 0.0065 (16.0)
from pCH110; Pharmacia LKB) directed by the HIV-1
promoter (21a). The pHIV/GAL plasmid was cotransfected
into Jurkat cells with the pU3R-III-CAT construct or pHIV-
CAT (17) and either the pHD1013 vector or the pEBV-RIE
plasmid. Two days after transfection, a portion of the extract
was used to determine the amount of GAL activity and
another portion was used to determine CAT activity. GAL
activity in cell lysates was determined by hydrolysis of the
substrate chlorophenol red P3-D-galactopyranoside (Boe-
rhinger-Mannheim Biochemicals) measured at 574 nm by
using the kinetic mode of the DU-70 spectrophotometer
(Beckman Instruments, Inc.) (21a). Transfection of the HIV-
CAT constructs with the BRLF1 transactivator resulted in a
9- to 15-fold increase in CAT activity (Table 2). A similar rise
in GAL activity in the same extracts was also detected in the
presence of the BRLF1 transactivator. Therefore, the level
of transactivation of the HIV-1 LTR was comparable when
either reporter gene was used; we conclude that BRLF1-
induced transactivation of the HIV-1 promoter is not due to
a reporter gene effect.
We have demonstrated that the EBV BRLF1 IE gene
product is able to transactivate the HIV-1 LTR. We have
shown that transactivation of the HIV-1 promoter by the
BRLF1 gene product, in contrast to that by BMLF1, is
independent of the reporter gene used and produces the
expected increase in CAT mRNA (16). Thus, if EBV-
induced transactivation of the HIV-1 promoter in cells
infected by both viruses does play a role in regulating HIV-1
expression, it is likely that such an effect is modulated by
BRLF1 rather than BMLF1.
A variety of different HIV-1 promoter deletions, including
5' deletions and site-directed mutations within the KB sites
and TATA box, retained the ability to be transactivated by
the BRLF1 gene product. Although some decreases in the
responses to the BRLF1 transactivator were noted in a
number of different deletion mutants, including those with
deletions involving the TATA box (pATATA) and the TAR
region (p-16/-17), no single deletion totally abolished
BRLF1 responsiveness. Computer-assisted homology scan-
ning did not reveal any sequence homology between the
HIV-1 LTR and the BRLF1-responsive region of the
BMLF1 promoter. These results suggest that optimal trans-
activation by BRLF1 may involve the combined effects of
more than one region of the HIV-1 promoter. The BRLF1
effect on HIV-1 promoter activity is thus comparable to the
previously described effects of the cytomegalovirus IE and
herpes simplex virus (ICPO and ICP4) transactivators. Each
of these herpesvirus transactivators can also increase HIV-1
LTR-directed CAT activity (and CAT mRNA). No single
region of the HIV-1 promoter has yet been shown to be
essential for transactivation by the ICP4, ICPO, or cytomeg-
alovirus IE transactivators, although the combined removal
of the NF-KB and Spl binding sites can markedly diminish
the transactivating effect (1, 8, 11, 21a, 24, 26, 27).
The EBV BRLF1 gene product is likely to mediate, at
least in part, the switch from latent to productive EBV
infection induced by BZLF1 (4, 5, 14, 35). The BRLF1 gene
is encoded in a region just upstream of the BZLF1 transac-
tivator (2), and the BRLF1 protein appears to be made from
bicistronic mRNAs containing both BRLF1 and BRLF1
open reading frames (21). Although the HIV-1 promoter is
responsive to the BRLF1 transactivator and not the BZLF1
transactivator (17), several EBV promoters have both
BRLF1- and BZLF1-responsive elements (4, 5, 14), and the
combined effects of both BZLF1 and BRLF1 are required
for optimal activation of certain EBV promoters (S. Kenney,
E. Holley-Guthrie, and E.-C. Mar, 14th Int. Herpesvirus
Workshop Abstr. p. 214, 1989). It has been previously
suggested that the BRLF1 gene product may function as an
enhancer transactivator while the BZLF1 gene product
transactivates promoters (21). We therefore anticipated that
BRLF1 transactivation of the HIV-1 LTR might be mediated
by the KB enhancer sequence. However, since we have
demonstrated that the enhancer region of the HIV-1 pro-
moter is not required for the BRLF1 response, it is likely
that BRLF1 transactivation can occur by at least two dif-
ferent mechanisms, one of which is enhancer independent.
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